Gene therapy has emerged as a promising approach to previously untreatable conditions, including Duchenne muscular dystrophy (DMD), a progressive disorder caused by DMD mutations that leads to early ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

The global cannabis use disorder treatment market is poised for strong growth, driven by rising cannabis consumption, the legalisation of cannabis for recreational and medicinal use, and increasing ...

A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address ...

Dimerix Ltd. sealed an exclusive license agreement with Amicus Therapeutics Inc. for commercialization of its phase III kidney disease candidate, DMX-200, in a deal valued at AU$940 million (US$601.22 ...